Vaxcyte, Inc. $PCVX Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 24.3% during the second quarter, HoldingsChannel reports. The firm owned 1,399,299 shares of the company’s stock after buying an additional 273,579 shares during the period. Jennison Associates LLC’s holdings in Vaxcyte were worth $45,491,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of PCVX. RA Capital Management L.P. lifted its stake in shares of Vaxcyte by 40.3% during the first quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company’s stock worth $460,262,000 after purchasing an additional 3,499,959 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Vaxcyte by 44.4% during the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock worth $242,303,000 after purchasing an additional 1,972,918 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in shares of Vaxcyte by 1,211.0% during the first quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company’s stock worth $24,200,000 after purchasing an additional 592,000 shares in the last quarter. Nuveen LLC acquired a new position in shares of Vaxcyte during the first quarter worth about $20,988,000. Finally, Fiera Capital Corp acquired a new position in shares of Vaxcyte during the first quarter worth about $13,563,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $44.75 on Friday. The business has a 50-day moving average of $36.73 and a 200-day moving average of $34.50. The company has a market capitalization of $5.81 billion, a PE ratio of -10.89 and a beta of 1.12. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $116.00.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same period last year, the business posted ($1.10) earnings per share. On average, equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Cowen restated a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, September 12th. They set a “neutral” rating and a $38.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.25.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.